Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial

Camilla M Hoyos¹, Brendon J Yee¹.².³, Craig L Phillips¹.⁴, Elizabeth A Machan¹, Ronald R Grunstein².³ and Peter Y Liu¹.⁵

¹Endocrine and Cardiometabolic Research Group and ²Sleep and Circadian Research Group, NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS), Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Royal North Shore Hospital, Sydney, Australia and ⁵Division of Endocrinology, Department of Medicine, David Geffen School of Medicine at UCLA, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, 1000 W Carson Street, Torrance, California 90502, USA

Correspondence should be addressed to P Y Liu
Email pliu@labiomed.org

The authors and the journal apologise for an error in Table 1 of this article published in the October 2012 (vol 167, issue 4, pp 531–541) issue of the European Journal of Endocrinology.

The error relates to the baseline testosterone values reported in Table 1. All other values for testosterone presented in the article are correct. The correct baseline values for testosterone in Table 1 should be as given below and not as published.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Testosterone</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone (nmol/l)</td>
<td>11.8 ± 3.7</td>
<td>12.1 ± 5.2</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Values are mean ± s.d. The P values were calculated by Student’s t-test.

The authors state that as these were transcription errors only in the table presenting baseline values, they did not have any influence on the statistical analyses presented.